CSL (ASX:CSL) share price down 8% after raising US$4.5bn

CSL's shares are back from their trading halt…

| More on:
A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has returned from its trading halt on Thursday morning.

At the time of writing, the biotherapeutics company's shares are down 8.5% to $272.51.

Why was the CSL share price halted?

The CSL share price was placed into a trading halt on Tuesday whilst it launched an equity raising.

The institutional component of the capital raising is now complete and raised US$4.5 billion (A$6.3 billion) at A$273.00 per new share. This represents an 8.2% discount to its last close price.

Management advised that the placement received strong support from existing shareholders and new investors.

CSL will now push ahead with its non-underwritten US$534 million (A$750 million) share purchase plan. These funds will be raised at the lower of the placement price and a 2% discount to the five-day volume weighted average price of CSL's shares up to and including the closing date.

CSL's Chief Executive Officer and Managing Director, Mr Paul Perreault, said "We appreciate the support we received from the investment community, including existing and new shareholders, for what is the largest ever primary equity raise in Australia. We are now pleased to launch our share purchase plan for eligible shareholders on Tuesday, 21 December 2021."

Why is CSL raising funds?

The proceeds from the equity raising will be used, along with new debt and existing cash reserves, to fund the acquisition of Swiss biotech giant Vifor Pharma for US$12.3 billion (A$17.2 billion) in cash.

Management notes that the deal expands its leadership across an attractive portfolio focused on renal disease and iron deficiency. It also highlights that Vifor has a high quality pipeline and complements CSL's existing therapeutic focus areas including Haematology, Thrombosis, Cardiovascular, and Transplant.

The deal is expected to be low-to-mid teens NPATA per share accretive in the first full year of CSL ownership, including full run rate cost synergies.

Mr Perreault, commented: "Vifor Pharma enhances CSL's patient focus and ability to protect the health of those facing a range of rare and serious medical conditions."

"It brings an outstanding team and a leading portfolio of products across Renal Disease and Iron Deficiency and a proven partnering and business development and licensing strategy. Vifor Pharma will also expand our presence in the rapidly growing nephrology market, while giving us the opportunity to leverage our complementary scientific expertise."

What was the response?

One leading broker that was particularly pleased with the deal was Citi. In response to the news, the broker upgraded CSL's shares to a buy rating with an improved price target of $340.00.

Based on the current CSL share price, this implies potential upside of 25% over the next 12 months.

Citi commented: "We calculate the acquisition to be ~9% accretive to NPATA per share (NPAT before acquisition-related amortization) – a proxy for cash flow."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Mergers & Acquisitions

a woman drawing image on wall of big fish about to eat a small fish
Mergers & Acquisitions

2 ASX shares with big takeover updates today

Investors are digesting just what the latest takeover updates could mean for these ASX shares.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Mergers & Acquisitions

Sigma share price: What's next with the Chemist Warehouse ASX listing?

What's next in this M&A saga?

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

This ASX All Ords stock is rocketing 20% after accepting a takeover offer

These two diagnostics companies are planning to merge their operations.

Read more »

A man packs up a box of belongings at his desk as he prepares to leave the office.
Mergers & Acquisitions

What will happen to CSR shares next week?

It's a huge month for ASX veteran CSR this June...

Read more »

A female miner wearing a high vis vest and hard hard smiles and holds a clipboard while inspecting a mine site with a colleague.
Materials Shares

Guess which ASX 200 mining stock is making a $276m UK acquisition

BHP failed in its UK takeover attempt but this mining stock is having more luck.

Read more »

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Mergers & Acquisitions

Guess which ASX 200 share just rocketed 15% on a $1.8 billion takeover offer

Investors are snapping up this ASX 200 share following confirmation of a takeover offer.

Read more »

Two CEOs shaking hands on a deal.
Mergers & Acquisitions

Guess which ASX All Ords stock is leaping 10% on a $1.3 billion bid

Deal accepted! This beaten-up stock is heading off the ASX.

Read more »

Two young male miners wearing red hardhats stand inside a mine and shake hands
Share Market News

Copper checkers: What's next for BHP shares after Anglo talks?

The miner's long term strategy hasn't changed.

Read more »